the planned divestiture of nonimaging businesses, Kodak strengthened its commitment to core photographic and medical film businesses. 

"Our growth strategies must apply equally to our traditional silver-halide film business as well as to digital imaging opportunities," said Kodak chairman George Fischer during his news conference announcing the Sterling divestiture plans. "I see a long future for the silver-halide business."

Kodak's medical film business has been growing strongly, Kohrt said, although the strongest growth has been in international markets. Kodak's electronic medical imaging business, including film for laser cameras, is growing faster than sales of traditional x-ray film.

Health Sciences recently dedicated a new worldwide headquarters for its Kodak Health Imaging Systems subsidiary in the Dallas area, he said. The subsidiary combined staff and technical resources from Vortech Data, a picture archiving and communications systems company acquired by Kodak, and some employees transferred from Rochester.

Electronic imaging manufacturing is split between Dallas and Rochester. Health Sciences maintains a joint sales force to approach hospital and other customers with both film and electronic imaging products. Health Imaging Systems provides technical expertise and support for electronically intensive accounts.

Contrast agent development takes up a large part of the overall Sterling Winthrop research and development budget. As of the start of last year, four out of seven Sterling pharmaceutical agents either in process or planned for release through 1997 were contrast agents (SCAN 12/30/92).

Pharmaceutical companies and drug prices have come under increased scrutiny as the U.S. searches for ways to slow health-care inflation. Drug suppliers counter that lower anticipated prices could put a damper on often lengthy and expensive pharmaceutical development projects. Some new imaging pharmaceuticals, such as Cytogen's monoclonal antibody nuclear imaging agent OncoScint, have been hampered in their launch in part because of their high cost per procedure.

While Sterling Winthrop is developing contrast agents on its own, much of the firm's current and future business involves manufacturing agents under license. Nycomed of Norway supplies the firm's most profitable contrast product, the nonionic radiographic agent Omnipaque, as well as the new Omniscan MRI agent. Sterling Winthrop has also obtained marketing rights for Advanced Magnetic's Feridex MRI agent in North America and Australia (SCAN 10/6/93).

Disclosures:

Source URL: